Testing for Breast Cancer

Transforming Breast Cancer Screening with Proactive Diagnostics

Breast cancer remains one of the most common cancers affecting women worldwide, and early detection continues to be the most powerful factor in improving survival and reducing the need for aggressive treatment. Traditional screening methods often identify cancer only after a tumour has formed, which limits the opportunity for truly early intervention. Tzar Labs is committed to changing this paradigm by introducing a proactive approach that identifies risk at the molecular level, long before structural changes appear on imaging.

The HrC test represents a new generation of breast cancer screening—one that focuses on prevention, precision, and early action. By analysing cancer‑initiating cells in the bloodstream, this test offers a clearer and earlier understanding of breast cancer risk than conventional methods alone.

Current Methods for Diagnosing Breast Cancer

Breast cancer screening typically begins during routine health assessments and involves several established diagnostic tools:

• Mammography: Low‑dose X‑ray imaging used to detect breast abnormalities or masses.
• Ultrasound or MRI: Advanced imaging used to investigate suspicious findings or dense breast tissue.
• Biopsy: A surgical procedure in which tissue samples are collected to confirm malignancy and determine cancer characteristics.

These methods have been essential in reducing breast cancer mortality, yet they are inherently reactive—they detect cancer only after physical changes have occurred.

Limitations of Conventional Breast Cancer Screening

Despite their importance, traditional diagnostic tools present several challenges that can delay or complicate early detection:

• Detection Threshold: Imaging can only identify tumours once they reach a visible size, meaning the earliest stages of cancer may remain undetected.
• False Positives: Benign cysts, hormonal changes, and dense breast tissue can mimic cancer on imaging, leading to unnecessary biopsies and anxiety.
• Invasiveness: Biopsies carry risks such as bleeding, infection, and emotional stress.
• Reduced Accuracy in Dense Breasts: Mammograms are less effective for women with dense breast tissue, increasing the risk of missed early cancers.

These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms.

The HrC Test: A Breakthrough in Early Breast Cancer Detection

The HrC test introduces a transformative approach to breast cancer screening by focusing on the earliest biological drivers of cancer. Instead of searching for tumours, the test isolates and analyses Cancer Stem Cells (CSCs)—the rare cells responsible for initiating cancer development.

A simple 12ml blood sample enables the HrC test to deliver:

• A 12–18 Month Early Warning Window: Detection of cancer‑initiating molecular activity long before imaging or biopsy can identify a mass.
• High Sensitivity and Clear Results: With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous screening outcomes.
• Reliable “Safe Zone” Assessment: A clear indication of “no risk” offers reassurance that breast cancer is not present and is unlikely to develop within the next year.

This proactive approach empowers women with earlier insights and greater control over their health.

Comprehensive Cancer Screening Through a Single Test

Pan‑Cancer Detection for Complete Health Protection

Although this document focuses on breast cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.

Key advantages include:

• Holistic Health Monitoring: Simultaneous assessment of breast cancer risk alongside other major cancers such as Bladder, Bowel, Cervical, Kidney, Leukaemia, Liver, Lung, Lymphoma, Ovarian, Pancreatic and Prostate.
• Actionable Insights: Early detection supports timely medical evaluation and preventive strategies.
• One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.

Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.

About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here